These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 2112756)
41. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Orstavik KH; Scheibel E; Ingerslev J; Schwartz M Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150 [TBL] [Abstract][Full Text] [Related]
42. Clotting factor concentrates. Entwistle CC Int Anesthesiol Clin; 1985; 23(2):49-59. PubMed ID: 3924836 [No Abstract] [Full Text] [Related]
43. Current treatment of patients with inhibitors to factor VIII. Hilgartner MW Haematologia (Budap); 1986; 19(1):21-32. PubMed ID: 3087840 [TBL] [Abstract][Full Text] [Related]
44. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia. Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287 [TBL] [Abstract][Full Text] [Related]
45. Preparation of modified bovine factor VIII with enhanced biological activity using insoluble-trypsin columns. Vogel CN; Parfitt HE; Kingdon HS; Lundblad RL Thromb Diath Haemorrh; 1973 Nov; 30(2):229-34. PubMed ID: 4773363 [No Abstract] [Full Text] [Related]
48. Factor VIII collection by pheresis. McLeod BC; Sassetti RJ; Cole ER; Pierce MI Lancet; 1980 Sep; 2(8196):671-3. PubMed ID: 6106786 [TBL] [Abstract][Full Text] [Related]
49. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII. Farrugia A Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537 [TBL] [Abstract][Full Text] [Related]
51. Pharmacology of anticoagulants. Quick AJ N Y State J Med; 1973 Jun; 73(12):1647-51. PubMed ID: 4513634 [No Abstract] [Full Text] [Related]
52. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma]. Mischke R Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358 [TBL] [Abstract][Full Text] [Related]
53. The use of chromatography to manufacture purer and safer plasma products. Johnston A; Adcock W Biotechnol Genet Eng Rev; 2000; 17():37-70. PubMed ID: 11255674 [No Abstract] [Full Text] [Related]
54. Report of the subcommittee on human factor VIII and factor IX preparations. Brinkhous KM Thromb Diath Haemorrh Suppl; 1968; 35():233. PubMed ID: 5761064 [No Abstract] [Full Text] [Related]
55. Human plasma fractionation and the impact of new technologies on the use and quality of plasma-derived products. Brodniewicz-Proba T Blood Rev; 1991 Dec; 5(4):245-57. PubMed ID: 1782484 [TBL] [Abstract][Full Text] [Related]
57. Influence of the primary anticoagulant on the recovery of factor VIII. Rock G Vox Sang; 1988; 54(2):125-6. PubMed ID: 3131962 [No Abstract] [Full Text] [Related]
58. Important parameters in plasma fractionation. Lane RS Vox Sang; 1986; 51 Suppl 1():49-51. PubMed ID: 3090786 [TBL] [Abstract][Full Text] [Related]
59. A comparison of factor VIII activity in cryoprecipitates prepared from ACD and CPD plasma. Shanberge JN; Gruhl MC; Ikemori R; Inoshita K; Chalos MK; Aster RH Transfusion; 1972; 12(4):251-8. PubMed ID: 5039460 [No Abstract] [Full Text] [Related]
60. One or two stage assay for factor VIII? Allain JP; Verroust F; Soulier JP Lancet; 1979 May; 1(8125):1076-7. PubMed ID: 86790 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]